BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today that Therabel has taken an equity stake in BioAlliance, according to the European licence agreement for Loramyc® and Setofilm® signed on March 31st 2010. Furthermore, the General Assembly Meeting, held on April 22, 2010, has adopted all the proposed resolutions, notably the change in the BioAlliance governance mode from a Supervisory Board to a Board of Directors.
This Board of Directors (composed of 8 members including 5 from the previous Supervisory Board) has appointed as planned a non executive Chairman, André Ulmann, who will also chair the Compensation Committee, in its meeting held immediately following the General Assembly. Dominique Costantini has been appointed Chief Executive Officer and Gilles Avenard Deputy Chief Executive Officer. The other independent members are Michel Arié, also Chairman of the Audit Committee, Gilles Marrache and Catherine Dunand*, new Board member. The Board also includes two shareholder representatives, ING Belgique represented by Denis Biju-Duval and AGF Private Equity represented by Rémi Droller.
“We are delighted with this equity investment by Therabel. This confirms our European strategic partnership which will ensure the commercial success of Loramyc® and Setofilm®, both products registered by BioAlliance Pharma. Therabel thus emphasizes its strategy to invest in the supportive care area in the hospital setting”, said Dominique Costantini, CEO of BioAlliance Pharma.
“This evolution of the Board allows us to be more reactive today. We would like to thank both leaving members of the Supervisory Board, Jean-Marie Zacharie and François Sarkozy. For many years they brought to the company their great professional experience. We are extremely glad of the diversity of this new Board of Directors which includes leading managers, shareholders’ representatives and independent members bringing their knowledge and expertise to the Company”, she added. “We wish to thank warmly our shareholders for their support in these major steps”.
Board member of Altavia group (communication and marketing group), she has been managing SMEs for 10 years, in a context of LBO in the health and communication areas. Previously, she held international management responsibilities in the pharmaceutical industry (Hoechst Roussel, Servier).
Catherine Dunand graduated from Ecole Centrale of Lyon and holds a MBA from INSEAD.